# A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

> **NCT05850520** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 892 (actual)

## Conditions studied

- Macular Edema Secondary to Retinal Vein Occlusion

## Interventions

- **DRUG:** Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose
- **DRUG:** Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
- **DRUG:** Sham
- **DIAGNOSTIC_TEST:** Fluorescein

## Key facts

- **NCT ID:** NCT05850520
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-15
- **Primary completion:** 2024-11-07
- **Final completion:** 2025-05-27
- **Target enrollment:** 892 (ACTUAL)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05850520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05850520, "A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05850520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*